萘普生治疗类风湿性关节炎。延长试验。
Naproxen in rheumatoid arthritis. Extended trial.
作者信息
Mowat A G, Ansell B M, Gumpel J M, Hill H F, Hill A G, Stoppard M
出版信息
Ann Rheum Dis. 1976 Dec;35(6):498-501. doi: 10.1136/ard.35.6.498.
121 patients with active rheumatoid arthritis, 91 of whom had proved intolerant of other nonsteroidal anti-inflammatory agents, were treated for a mean of 10 months with naproxen. A dosage of 250 mg twice daily produced sustained improvement in most of the standard clinical measurements. 28 patients complained of side effects, with a lower than expected incidence of gastrointestinal complaints and no drug-induced rash being recorded. 19 patients withdrew from the trial because of side effects, while a further 22 withdrew because the drug was ineffective. Naproxen is a useful drug for long-term use in patients with rheumatoid arthritis, including those who have proved intolerant of or experienced inadequate symptomatic relief from other nonsteriodal anti-inflammatory agents.
121例活动性类风湿性关节炎患者，其中91例已证实对其他非甾体抗炎药不耐受，接受萘普生治疗，平均治疗时间为10个月。每日两次250毫克的剂量在大多数标准临床测量中产生了持续改善。28例患者抱怨有副作用，胃肠道不适的发生率低于预期，且未记录到药物引起的皮疹。19例患者因副作用退出试验，另有22例因药物无效而退出。萘普生是一种可用于类风湿性关节炎患者长期治疗的有用药物，包括那些已证实对其他非甾体抗炎药不耐受或症状缓解不足的患者。
Zotero 插件